NCT02976857CompletedPhase 1
A Phase 1 Single Center, Non-randomized Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Refractory Diffuse Large B-cell Lymphoma
Shanghai AbelZeta Ltd.1 site in 1 country15 target enrollmentStarted: December 1, 2016Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- Dose-limiting toxicity (DLT)
Study Overview
Brief Summary
The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR011 in treatment of refractory DLBCL
Detailed Description
The 3x3 dose escalation design will be adopted in order to determine the maximum tolerated dose (MTD). Subjects will be enrolled into low-dose group, medium-dose group and high-dose group as below:
Dose CAR+ cells/kg
Low 0.8×106
Medium 2.5×106
High 5.0×106
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically diagnosed as DLBCL according to the NCCN non-Hodgkin's lymphoma Clinical Practice Guidelines (3rd edition 2016)
- •Refractory DLBCL
- •All subjects must have received adequate prior therapy including anti-CD20 monoclonal antibody (unless tumor is CD20-negative) and an anthracycline containing chemotherapy regimen. The standardized treatment regimens reference to NCCN non-Hodgkin lymphoma Clinical Practice Guidelines (2016 Version 3)
- •At least one measurable lesion per revised IWG Response Criteria (the longest diameter of the tumor ≥ 1.5 cm)
- •Age 18-70 years old, male or female
- •Expected survival ≥ 12 weeks
- •ECOG score 0-1
- •Subject's left ventricular ejection fraction (LVEF) is ≥ 50% and no evidence of pericardial effusion as determined by an ECHO
- •At least 4 weeks from receiving previous treatment (radiotherapy, chemotherapy, monoclonal antibody therapy or other treatments)
- •No contraindications of peripheral blood apheresis
- •Female subjects in childbearing age, their serum or urine pregnancy test must be negative, and must agree to take effective contraceptive measures during the trial measures
- •Volunteered to participate in this study and signed informed consent
Exclusion Criteria
- •Have a history of allergy to cellular products
- •Used any genetically modified T cell therapy
- •History of allogeneic hematopoietic stem cell transplantation
- •Severe active infection (uncomplicated urinary tract infections, bacterial pharyngitis allowed) or currently receiving intravenous antibiotic therapy and received intravenous antibiotic therapy within one week. Prophylactic antibiotic, antiviral and antifungal treatment is permissible
- •Hepatitis B or hepatitis C virus infection (including carriers), as well as acquired, congenital immune deficiency diseases, including but not limited to HIV-infected persons
- •Patients with class III and IV heart failure according to the NYHA Heart Failure Classifications
- •A history of QT prolongation
- •A history of epilepsy or other central nervous system disorders
- •The patient had a history of other primary cancers, with the following exceptions: Excisional non-melanoma such as cutaneous basal cell carcinoma; Cured in situ carcinoma such as cervical cancer, bladder cancer or breast cancer
- •Subjects with any autoimmune disease or any immune deficiency disease or other disease in need of immunosuppressive therapy
- •Used of systemic steroids within two weeks (using inhaled steroids is an exception)
- •Women who are pregnant or lactating or have breeding intent in 6 months
- •Participated in any other clinical trial within three months
- •The investigators believe that any increase in the risk of the subject or interference with the results of the trial
Arms & Interventions
C-CAR011
Experimental
C-CAR011 infusion In the first cell therapy 0, 1 and 2 days, respectively 10%, 30% and 60% ratio three times reinfusion.
Intervention: C-CAR-011 (Biological)
Outcomes
Primary Outcomes
Dose-limiting toxicity (DLT)
Time Frame: 28 days
Non-haematological dose-limiting toxicities was any toxicity of grade 3 or higher occurring within 28 days of C-CAR011 infusion judged possibly related to the treatment regimen.The following toxicities were not considered dose limiting toxicities: tumor lysis syndrome, abnormal electrolytes responding to supplementation, hypoalbuminemia, liver dysfunction resolving to ≤grade 2 within 14 days, transient (\<72 hours) grade 4 hepatic enzyme abnormality, and grade 3 or 4 fever or neutropenic fever.
Secondary Outcomes
- Overall response rate(4 and 12 weeks)
- Disease control rate(12 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 1
A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALLRelapsed or Refractory Acute Lymphoblastic LeukemiaNCT03018093Shanghai AbelZeta Ltd.20
Recruiting
Phase 1
Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCCHepatocellular CarcinomaNCT04443309Peking Union Medical College Hospital53
Unknown
Phase 1
Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MMMultiple MyelomaNCT04500431Shanghai Tongji Hospital, Tongji University School of Medicine10
Unknown
Phase 2
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy SubjectsLymphoma, B-CellLeukemia, B-cellNCT03598179The First Affiliated Hospital with Nanjing Medical University10
Withdrawn
Phase 1
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT05248685Beijing Boren Hospital20